References
- Broeckling CD, Yao L, Isaac G, Gioioso M, Ianchis V, Vissers JPC. 2021. Application of predicted collisional cross section to metabolome databases to probabilistically describe the current and future ion mobility mass spectrometry. J Am Soc Mass Spectrom. 32(3):661–669.
- Camenisch GP. 2016. Drug disposition classification systems in discovery and development: a comparative review of the BDDCS, ECCS and ECCCS concepts. Pharm Res. 33(11):2583–2593.
- de Bruyn Kops C, Šícho M, Mazzolari A, Kirchmair J. 2021. GLORYx: prediction of the metabolites resulting from Phase 1 and Phase 2 biotransformations of xenobiotics. Chem Res Toxicol. 34(2):286–299.
- Gao H, Obach RS. 2011. Addressing MIST (Metabolites in Safety Testing): bioanalytical approaches to address metabolite exposures in humans and animals. Curr Drug Metab. 12(6):578–586.
- Higton D, Palmer ME, Vissers JPC, Mullin LG, Plumb RS, Wilson ID. 2021. Use of cyclic ion mobility spectrometry (cIM)-mass spectrometry to study the intramolecular transacylation of Diclofenac acyl glucuronide. Anal Chem. 93(20):7413–7421.
- Lozac’h F, Fahrni S, Maria DD, Welte C, Bourquin J, Synal H-A, Pearson D, Walles M, Camenisch G. 2018. Evaluation of cAMS for 14C microtracer ADME studies: opportunities to change the current drug development paradigm. Bioanalysis. 10(5):321–339.
- Šícho M, Stork C, Mazzolari A, de Bruyn Kops C, Pedretti A, Testa B, Vistoli G, Svozil D, Kirchmair J. 2019. FAME 3: predicting the sites of metabolism in synthetic compounds and natural products for Phase 1 and Phase 2 metabolic enzymes. J Chem Inf Model. 59(8):3400–3412.
- Surapaneni S, Yerramilli U, Bai A, Dalvie D, Brooks J, Wang X, Selkirk JV, Yan YG, Zhang P, Hargreaves R, et al. 2021. Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of Ozanimod, a novel Sphingosine 1-phosphate receptor modulator. Drug Metab Dispos. 49(5):405–419.
- Takahashi RH, Khojasteh C, Wright M, Hop CECA, Ma S. 2017. Mixed matrix method provides a reliable metabolite exposure comparison for assessment of metabolites in safety testing (MIST). Drug Metab Lett. 11(1):21–28.
- Weidolf L, Andersson T, Bercu JP, Brink A, Glowienke S, Harvey J, Hayes MA, Jacques P, Lu C, Manevski N, et al. 2020. Qualification of impurities based on metabolite data. Regul Toxicol Pharmacol. 110:104524.
- Zeller A, Brigo A, Brink A, Guerard M, Lang D, Muster W, Runge F, Sutter A, Vock E, Wichard J, et al. 2020. Genotoxicity assessment of drug metabolites in the context of MIST and beyond. Chem Res Toxicol. 33(1):10–19.